SubHero Banner

Ninlaro®(ixazomib) – Updated labeling

April 28, 2022 - The FDA added a limitation of use for Takeda’s Ninlaro (ixazomib), stating that Ninlaro is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials.

Download PDF